The simulation models how immune cell activation releases IL-6 and TNF-alpha that recruit further immune cells, showing how the resulting positive-feedback loop either resolves naturally or crosses a runaway threshold.
Adjust the initial trigger strength and the negative-feedback strength sliders to see whether the cytokine cascade settles back to baseline or spirals past the runaway threshold in the 3D visualization.
Sliders for trigger strength and negative-feedback strength, with a 3D view of immune cell recruitment and cytokine spread
The interleukin-6 blocking drug tocilizumab was originally developed for rheumatoid arthritis decades before it became a standard treatment for cytokine release syndrome caused by CAR-T cancer therapy.
The simulation models how immune cell activation releases IL-6 and TNF-alpha that recruit further immune cells, showing how the resulting positive-feedback loop either resolves naturally or crosses a runaway threshold.
The simulation models how immune cell activation releases IL-6 and TNF-alpha that recruit further immune cells, showing how the resulting positive-feedback loop either resolves naturally or crosses a runaway threshold.
Adjust the initial trigger strength and the negative-feedback strength sliders to see whether the cytokine cascade settles back to baseline or spirals past the runaway threshold in the 3D visualization.
The interleukin-6 blocking drug tocilizumab was originally developed for rheumatoid arthritis decades before it became a standard treatment for cytokine release syndrome caused by CAR-T cancer therapy.